San Francisco-Three-year FDA clinical trial outcome data support the safety, efficacy, and predictability of the Implantable Contact Lens (ICL, STAAR Surgical) for the treatment of moderate to high myopia, said Stephen G. Slade, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
